Effects of X-ray irradiation on the overexpression of HER2/Erb-B2 on breast cancer cell lines

被引:0
作者
Juranic, ZD
Borojevic, N
Jovanovic, D
Stanojevic-Bakic, N
Zizak, Z
Neskovic-Konstantinovic, Z
Saric, N
Stanojkovic, T
Raonic, T
Milosevic, D
机构
[1] Inst Oncol & Radiol Serbia, Dept Expt Oncol, YU-11000 Belgrade, Serbia Monteneg, Serbia
[2] Inst Oncol & Radiol Serbia, Dept Radiotherapy, YU-11000 Belgrade, Serbia Monteneg, Serbia
[3] Inst Oncol & Radiol Serbia, Dept Pathol, YU-11000 Belgrade, Serbia Monteneg, Serbia
[4] Inst Oncol & Radiol Serbia, Dept Med Oncol, YU-11000 Belgrade, Serbia Monteneg, Serbia
关键词
HER-2; receptors; irradiation; MDA-MB-361 and MDA-MB-453 breast carcinoma cell lines; cytotoxicity;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Irradiation is the conventional treatment modality for cancer patients. However. besides its cytotoxic effects on malignant cells it might also affect the biology of surviving cells. Since overexpression of HER-2 receptors on malignant cells Is a prerequisite for the therapeutic efficacy of Herceptin, it seems important to know whether previous irradiation changes their overexpression. The experiments performed in this work were aimed to determine whether X-ray Irradiation of MDA-MB-361 and MDA-MB-453 breast carcinoma cell lines. besides its cytotoxic action, affects the overexpression of HER-2 protein. Determination of the cytotoxic effect of X-ray irradiation was done using trypan blue test. The breast carcinoma cell responsiveness to herceptin treatment in the presence of 10% fresh human serum (from healthy volunteer's) in the presence or absence of 25 mug/ml of herceptin, in vitro before and after cell-irradiation, was evaluated by MTT test. The degree of HER-2 overexpression was determined by immunocytochemistry, using DAKO(TM) HercepTest. Preliminary results obtained in this work showed that X-ray irradiation, besides its cytotoxic effect oil malignant cells, could lead to overexpression of HER-2 receptors on (initially by immunocytochemistry, HER-2 negative) tumor cells. Indicating change in biology of treated tumor cells. Further investigation in this direction will probably be helpful to elucidate this task in order to improve the selection of irradiated patients for Herceptin therapy.
引用
收藏
页码:675 / 680
页数:6
相关论文
共 14 条
[1]  
Baselga J, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.28544
[2]   SOME PRACTICAL CONSIDERATIONS AND APPLICATIONS OF THE NATIONAL-CANCER-INSTITUTE IN-VITRO ANTICANCER DRUG DISCOVERY SCREEN [J].
BOYD, MR ;
PAULI, KD .
DRUG DEVELOPMENT RESEARCH, 1995, 34 (02) :91-109
[3]   HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY [J].
CARTER, P ;
PRESTA, L ;
GORMAN, CM ;
RIDGWAY, JBB ;
HENNER, D ;
WONG, WLT ;
ROWLAND, AM ;
KOTTS, C ;
CARVER, ME ;
SHEPARD, HM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4285-4289
[4]  
DEVINE D V, 1991, Transfusion Medicine Reviews, V5, P123, DOI 10.1016/S0887-7963(91)70199-5
[5]  
Fukutomi T, 1992, Nihon Geka Gakkai Zasshi, V93, P183
[6]   Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer [J].
Järvinen, TAH ;
Tanner, M ;
Rantanen, V ;
Bärlund, M ;
Borg, Å ;
Grénman, S ;
Isola, J .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (03) :839-847
[7]  
JURANIC Z, 2002, ARCH ONCOLOGY, V10, P162
[8]   DIFFERENTIAL RESPONSES OF HUMAN TUMOR-CELL LINES TO ANTI-P185(HER2) MONOCLONAL-ANTIBODIES [J].
LEWIS, GD ;
FIGARI, I ;
FENDLY, B ;
WONG, WL ;
CARTER, P ;
GORMAN, C ;
SHEPARD, HM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1993, 37 (04) :255-263
[9]   RAPID COLORIMETRIC ASSAY FOR THE QUANTIFICATION OF LEUKEMIA INHIBITORY FACTOR (LIF) AND INTERLEUKIN-6 (IL-6) [J].
OHNO, M ;
ABE, T .
JOURNAL OF IMMUNOLOGICAL METHODS, 1991, 145 (1-2) :199-203
[10]  
Rhodes A, 2002, AM J CLIN PATHOL, V118, P408